The global urological cancers market is projected to double by 2022 and reach $35.9bn growing at a compound annual growth rate (CAGR) of 10.39%, up from $17.9bn in 2015, according to a report by GBI Research.
Titled 'Global Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics', the report states that the urological cancers market includes bladder, kidney, prostate and testicular cancers and the growth of this space will be propelled by new targeted therapies for bladder cancer.
The increase in market value will also be supported by the growing incidence of prostate and kidney cancer.
New checkpoint inhibitors are expected to be introduced to help in reducing the associated toxicity of urological cancer therapies.
They will be increasingly used for treating patients with low functional status.
The launch of targeted therapies will enhance the survival chances of the patients and enable the administration of an increased number of chemotherapy rounds.
The treatment space of urological cancer will be reshaped by the launch of Roche's atezolizumab and AstraZeneca's durvalumab for the treatment of bladder cancer. The two drugs are projected to capture the market, with atezolizumab anticipated to achieve revenue of $2.5bn in 2022 and durvalumab positioned to generate $1.2bn.
Roche's drug is expected to receive approval later this year, while AstraZeneca will receive approval for its drug in 2017. The success of these drugs will be largely driven by a lack of targeted treatment for bladder cancer and a rise in the number of cases.
The introduction of these drugs is expected to alter the market landscape, while the currently available drugs will continue to dominate in terms of revenue, due to market competition.
Analyst for GBI Research Adam Bradbury explains: "Key players Johnson & Johnson and Pfizer, for example, are predicted to have decreasing market shares due to decreasing or static drug revenues as the overall market revenues rise.
"Those of Roche and Bristol-Myers Squibb (BMS), on the other hand, will increase due to the uptake of recently approved and upcoming immune checkpoint inhibitors such as atezolizumab, and BMS's Opdivo and Yervoy.
"Astellas is forecast to maintain its strong market share through to 2022 due to increasing Xtandi revenues."